Tinzaparin blood-thinner and biomarkers after ovarian cancer surgery
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether the blood thinner tinzaparin used after neoadjuvant treatment can change blood markers (“biomarkers”) in people with certain stages of ovarian cancer. It aims to understand if tinzaparin affects the body’s cancer-related signals, which could help future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree in writing to take part in the study
- You are 18 years or older
- Your cancer is epithelial ovarian, fallopian tube, or peritoneal cancer (or an abdominal cancer that biopsy shows started in those areas), and it is high-grade serous, endometrioid, or clear cell
- Your cancer is FIGO stage III or IV and you are planning platinum-based chemotherapy
- Your blood counts and kidney function must be high enough: eGFR 30 or higher, and platelets at least 100
- You cannot currently be pregnant or breastfeeding, and you must use reliable birth control if you could get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This study tests a combination of two targeted therapies, fluzoparib (a PARP inhibitor) and apatinib (a blood vessel blocker), as maintenance treatment after initial chemotherapy for advanced ovarian cancer. The goal is to see if this combination helps keep the cancer from coming back longer than usual.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This study is testing whether a simple blood test can help predict how well the drug niraparib works as a maintenance treatment after initial chemotherapy for advanced ovarian cancer. It aims to find markers in the blood that are linked to treatment response.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.